Exhibit 5.1
John T. McKenna
+1 650 843 5059
jmckenna@cooley.com
September 1, 2020
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Ladies and Gentlemen:
We have acted as counsel to Immunovant, Inc., a Delaware corporation (the Company), in connection with the filing by the Company of a Registration Statement on Form S-1 (No. 333-248498) (the Initial Registration Statement) with the Securities and Exchange Commission, including the prospectus which forms a part of the Initial Registration Statement (the Prospectus), and a Registration Statement on Form S-1 related thereto filed pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended (the 462(b) Registration Statement and, together with the Initial Registration Statement, the Registration Statements), covering an underwritten public offering of up to 6,060,606 shares of the Companys common stock, par value $0.0001 (Shares), including up to 790,513 Shares that may be sold pursuant to the exercise of an option to purchase additional Shares.
In connection with this opinion, we have examined and relied upon (a) the Registration Statements and the Prospectus, (b) the Companys Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, and (c) originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have undertaken no independent verification with respect to such matters.
We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statements and the Prospectus, will be validly issued, fully paid and non-assessable.
Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130
t: (650) 843-5000 f: (650) 849-7400 cooley.com
Immunovant, Inc.
September 1, 2020
Page Two
We consent to the reference to our firm under the caption Legal Matters in the Prospectus included in the Initial Registration Statement and to the filing of this opinion as an exhibit to an amendment to the Initial Registration Statement filed pursuant to Rule 462(d) under the Securities Act of 1933, as amended.
Sincerely,
Cooley LLP
By: | /s/ John T. McKenna | |
John T. McKenna |
Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130
t: (650) 843-5000 f: (650) 849-7400 cooley.com